ADCs

With over ten years of experience supporting antibody drug conjugate (ADC) discovery, development and manufacturing, our multidisciplinary team has worked with a range of different antibodies, linkers and toxins to enable us to develop customised bioconjugation approaches and offer complex ADC solutions to our customers.

Measurement of ADC stability in serum via subunit DAR analysis

One pager3 min read

Measurement of ADC stability in serum via subunit DAR analysis

Stability of biologics is a critical quality attribute (CQA) affecting the levels of dosing and efficacy.

Read more

Popular in this category

Peptide digestion analysis of an antibody drug conjugate

One pager3 min read

Peptide digestion analysis of an antibody drug conjugate Read more

Sterling's Deeside, UK facility

Article6 min read

Partnering for ADCs: What to look for in a contract development and manufacturing organisation (CDMO) Read more

Blog5 min read

Overcoming purification hurdles for ADC linker payloads Read more

News2 min read

Kivu Bioscience Selects Sterling for cGMP Manufacturing of Lead Oncology ADC Read more

All articles

Stability of ADC linker payloads in sub-cellular fractions

One pager3 min read

Stability of ADC linker payloads in sub-cellular fractions Read more

ADCs at Sterling

News2 min read

GlycoNex Announces Manufacturing Agreement with Sterling for GNX102-ADC Clinical Trial Production Read more

News2 min read

Sterling Expands GMP ADC Manufacturing Capacity at Deeside, UK Read more

Mass spectrometry

Infographic1 min read

Measurement of ADC stability in plasma and serum via mass spectrometry analysis Read more

ADCs

One pager2 min read

Antibody drug conjugation (ADC) overview Read more

Preview of the applying analytical method validation to cell-based potency assays whitepaper

Whitepaper12 min read

Applying analytical method validation to cell-based potency assays Read more

Sterling's Deeside, UK facility

News2 min read

Sterling Expands Bioanalytical Capabilities at Deeside, UK Site Read more

Mass spectrometry

One pager3 min read

Stability of ADCs in sub-cellular fractions Read more

Stability of ADC toxins in sub-cellular fractions

One pager3 min read

Stability of ADC toxins in sub-cellular fractions Read more

Next Page »

Explore more

All ADCs API Development API Manufacturing Analytical Services Drug Discovery Facilities News PDMO People Peptides Sustainability Technologies

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

Phone

This field is for validation purposes and should be left unchanged.

Name(Required)

Email(Required)

Company Name(Required)

This field is hidden when viewing the form

Prospect Source

Please click here for our privacy policy

Service. Passion. Science.

PDMO^® is registered in the U.S. Patent and Trademark Office.

PDMO^® is a registered trademark of Sterling Pharma Solutions Limited (EUIPO and UKIPO). All rights reserved.

Sterling Pharma Solutions Limited. Registration number: 05712796. Registered office address: Dudley Lane, Dudley, Cramlington, NE23 7QG, United Kingdom. Registered in England.